ContractSchuler Jack W • August 16th, 2013 • Orthopedic, prosthetic & surgical appliances & supplies • Delaware
NEITHER THIS WARRANT, NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT (COLLECTIVELY, THE “SECURITIES”), HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER ANY STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE OFFERED, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES OR BLUE SKY LAWS, PURSUANT TO REGISTRATION OR QUALIFICATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE REASONABLY SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER IS IN COMPLIANCE WITH THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES OR BLUE SKY LAWS. THIS WARRANT IS SUBJECT TO THE TRANSFER RESTR
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 6th, 2020 • Schuler Jack W • In vitro & in vivo diagnostic substances • Delaware
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) dated July 1, 2020, is entered into by and between (i) Aspira Women’s Health Inc., a Delaware corporation (the “Company”), and (ii) the investor listed on Schedule I (including its successors and permitted assigns, the “Investor”). To the extent that there are multiple Investors listed on Schedule I, all references herein to “the Investor” shall refer to each such Investor, severally and not jointly.
TRANSITION THERAPEUTICS INC. (Existing under the Business Corporations Act (Ontario)) Common Share Purchase WarrantsSchuler Jack W • July 2nd, 2014 • Medicinal chemicals & botanical products • Ontario
SUBSCRIPTION AGREEMENT FOR UNITSSubscription Agreement • July 2nd, 2014 • Schuler Jack W • Medicinal chemicals & botanical products • Ontario
The undersigned (hereinafter referred to as the Subscriber) hereby irrevocably subscribes for and agrees to purchase the number of units of the Corporation (Units) set forth below for the aggregate subscription price set forth below (the Aggregate Subscription Price), representing a subscription price of US$5.32 per Unit, upon and subject to the terms and conditions set forth in “Terms and Conditions of Subscription for Units of Transition Therapeutics” attached hereto (together with the face pages and the attached Exhibits, the Subscription Agreement). Each Unit consists of (i) one common share in the capital of the Corporation (a Common Share) and (ii) 0.61 Common Share purchase warrant with a purchase price of US$7.10 per whole Warrant (a Warrant), with each whole Warrant entitling the holder thereof to purchase one Common Share for a period of twenty four months from the Closing Date (as defined herein).
STANDBY PURCHASE AGREEMENTStandby Purchase Agreement • March 19th, 2014 • Schuler Jack W • Laboratory analytical instruments • Delaware
This STANDBY PURCHASE AGREEMENT (this “Agreement”) is made and entered into on March 10, 2014, by and among Schuler Family Foundation (the “Foundation”), Jack Schuler, Trustee of the Jack W. Schuler Living Trust (the “Trustee”) (the Foundation and Trustee, collectively, the “Standby Purchasers,” and each individually, a “Standby Purchaser”), and Accelerate Diagnostics, Inc., a Delaware corporation (the “Company”).
Joint Filing AgreementJoint Filing Agreement • February 8th, 2018 • Schuler Jack W • Pharmaceutical preparations
The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.
SUBSCRIPTION AGREEMENT FOR UNITSSchuler Jack W • August 22nd, 2013 • Medicinal chemicals & botanical products • Ontario
The undersigned (hereinafter referred to as the Subscriber) hereby irrevocably subscribes for and agrees to purchase the number of units of the Corporation (Units) set forth below for the aggregate subscription price set forth below (the Aggregate Subscription Price), representing a subscription price of US$4.19 per Unit, upon and subject to the terms and conditions set forth in “Terms and Conditions of Subscription for Units of Transition Therapeutics” attached hereto (together with the face pages and the attached Exhibits, the Subscription Agreement). Each Unit consists of (i) one common share in the capital of the Corporation (a Common Share), (ii) 0.325 Common Share purchase warrant with a purchase price of US$4.60 per whole Warrant (the 460 Warrants), and (iii) 0.400 Common Share purchase warrant with a purchase price of US$6.50 per whole Warrant (the 650 Warrants and collectively with the 460 Warrants, the Warrants), with each whole Warrant entitling the holder thereof to purchas
Joint Filing AgreementJoint Filing Agreement • July 2nd, 2014 • Schuler Jack W • Medicinal chemicals & botanical products
This Joint Filing Agreement is entered into as of July 1, 2014, by the undersigned, who hereby agree that the Statement on Amendment No. 2 to Schedule 13D in respect of the common shares ofTransition Therapeutics Inc. is, and any amendment subsequently signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • August 16th, 2013 • Schuler Jack W • Orthopedic, prosthetic & surgical appliances & supplies
This Joint Filing Agreement is entered into as of August 15, 2013, by the undersigned, who hereby agree that the Statement on Schedule 13D with respect to the shares of the common stock, par value $0.0001 per share, of Hansen Medical, Inc., a Delaware corporation, is, and any amendment subsequently signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
ASSIGNMENTSchuler Jack W • November 10th, 2014 • Dental equipment & supplies
Effective immediately, Jack W. Schuler Living Trust (the “Trust”) hereby transfers and assigns to Schuler Family Foundation (the “Foundation”) all of its rights and obligations under that certain Securities Purchase Agreement, dated November 3, 2014, by and among Biolase, Inc. (the “Company”).
JOINT FILING AGREEMENTJoint Filing Agreement • October 5th, 2021 • Schuler Jack W • Laboratory analytical instruments
In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned parties hereby agrees to file jointly Amendment No. 9 to Schedule 13D (including any amendments thereto) (the “Statement”) with respect to the common stock, $0.001 per share par value (the “Common Stock”), of Accelerate Diagnostics, Inc., a Delaware corporation.
AGREEMENT TO BE BOUNDSchuler Jack W • November 10th, 2014 • Dental equipment & supplies
For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Schuler Family Foundation hereby represents, warrants, covenants and agrees to become a party to and be bound by the provisions of that certain Securities Purchase Agreement, dated November 3, 2014, by and among Biolase, Inc., a Delaware corporation, and each person listed on Schedule I thereto that apply to the “Investors.”
JOINT FILING AGREEMENTJoint Filing Agreement • February 11th, 2016 • Schuler Jack W • Medicinal chemicals & botanical products
This Joint Filing Agreement is entered into as of February 11, 2016, by the undersigned, who hereby agree that the Statement on Amendment No. 3 to Schedule 13D in respect of the common shares of Transition Therapeutics Inc. is filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • August 22nd, 2013 • Schuler Jack W • Medicinal chemicals & botanical products
This Joint Filing Agreement is entered into as of August 21, 2013, by the undersigned, who hereby agree that the Statement on Amendment No. 1 to Schedule 13D in respect of the common shares ofTransition Therapeutics Inc. is, and any amendment subsequently signed by each of the undersigned shall be, filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
Joint Filing AgreementJoint Filing Agreement • February 14th, 2017 • Schuler Jack W • Pharmaceutical preparations
The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.
Joint Filing AgreementJoint Filing Agreement • February 11th, 2016 • Schuler Jack W • Pharmaceutical preparations
The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.
JOINT FILING AGREEMENTJoint Filing Agreement • November 10th, 2014 • Schuler Jack W • Dental equipment & supplies
The undersigned hereby agree that the statement on Schedule 13D with respect to the common stock of Biolase, Inc. dated as of November 7, 2014 is, and any amendments thereto (including amendments on Schedule 13G) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934.
JOINT FILING AGREEMENTJoint Filing Agreement • November 10th, 2014 • Schuler Jack W • Dental equipment & supplies
The undersigned hereby agree that the statement on Schedule 13D with respect to the common stock of Biolase, Inc. dated as of November 7, 2014 is, and any amendments thereto (including amendments on Schedule 13G) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934.
